• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

    7/15/24 4:30:32 PM ET
    $QDEL
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QDEL alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

    QuidelOrtho Corporation

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    219798105

    (CUSIP Number)

     

    Jeffrey Ferguson

    The Carlyle Group

    1001 Pennsylvania Avenue, NW

    Suite 220 South

    Washington, D.C. 20004

    (202) 729-5626

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    July 11, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 219798105 13D Page 1 of 13 pages

     

    1

    Names of Reporting Persons

     

    The Carlyle Group Inc.

     
    2

    Check the Appropriate Box if a Member of a Group

     

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    CO

     

     

     

     

    CUSIP No. 219798105 13D Page 2 of 13 pages

     

    1

    Names of Reporting Persons

     

    Carlyle Holdings II GP L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 3 of 13 pages

     

    1

    Names of Reporting Persons

     

    Carlyle Holdings II L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

     

    (a) ☐

    (b)☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 4 of 13 pages

     

    1

    Names of Reporting Persons

     

    CG Subsidiary Holdings L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

     

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 5 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group Cayman Investment Holdings, L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 6 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group Cayman Investment Holdings Sub L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 7 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group VI Cayman, L.L.C.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

     

     

     

     

    CUSIP No. 219798105 13D Page 8 of 13 pages

     

    1

    Names of Reporting Persons

     

    TC Group VI Cayman, L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 9 of 13 pages

     

    1

    Names of Reporting Persons

     

    Carlyle Partners VI Cayman Holdings, L.P.

     
    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

     
    4

    Source of Funds (See Instructions)

     

    OO

     
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐

     

     
    6

    Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    11,045,002

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    11,045,002

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    11,045,002

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    16.5%

    14

    Type of Reporting Person

     

    PN

     

     

     

     

    CUSIP No. 219798105 13D Page 10 of 13 pages

     

    Explanatory Note

     

    This Amendment No. 3 to Schedule 13D (this “Amendment No. 3”) amends and supplements the statement on Schedule 13D filed with the United States Securities and Exchange Commission (the “SEC”) on June 6, 2022 (the “Schedule 13D”), relating to the common stock, par value $0.001 per share (the “Common Stock”), of QuidelOrtho Corporation, a Delaware corporation (the “Issuer”), whose principal executive office is located at 9975 Summers Ridge Road, San Diego, California 92121. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

     

     

     

     

    CUSIP No. 219798105 13D Page 11 of 13 pages

     

    Item 5.Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b) The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Common Stock and percentage of Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 66,971,816 shares of Common Stock outstanding as of May 1, 2024, as disclosed in the Issuer’s quarterly report on Form 10-Q filed on May 9, 2024.

     

    Reporting Person 

    Amount

    beneficially

    owned

      

    Percent

    of class

       Sole power to vote or to direct the vote   Shared power to vote or to direct the vote   Sole power to dispose or to direct the disposition   Shared power to dispose or to direct the disposition 
    The Carlyle Group Inc.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    Carlyle Holdings II GP L.L.C.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    Carlyle Holdings II L.L.C.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    CG Subsidiary Holdings L.L.C.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    TC Group Cayman Investment Holdings, L.P.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    TC Group Cayman Investment Holdings Sub L.P.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    TC Group VI Cayman, L.L.C.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    TC Group VI Cayman, L.P.   11,045,002    16.5%   0    11,045,002    0    11,045,002 
    Carlyle Partners VI Cayman Holdings, L.P.   11,045,002    16.5%   0    11,045,002    0    11,045,002 

     

    Reflects shares of Common Stock held of record by Carlyle Partners VI Cayman Holdings, L.P. The Carlyle Group Inc., a publicly traded company listed on Nasdaq, is the sole member of Carlyle Holdings II GP L.L.C., which is the managing member of Carlyle Holdings II L.L.C., which, with respect to the securities reported herein, is the managing member of CG Subsidiary Holdings L.L.C., which is the general partner of TC Group Cayman Investment Holdings, L.P., which is the general partner of TC Group Cayman Investment Holdings Sub L.P., which is the sole member of TC Group VI Cayman, L.L.C., which is the general partner of TC Group VI Cayman, L.P., which is the general partner of Carlyle Partners VI Cayman Holdings, L.P. Accordingly, each of the foregoing entities may be deemed to share beneficial ownership of the securities held of record by Carlyle Partners VI Cayman Holdings, L.P., but each disclaims beneficial ownership of such securities.

     

     

     

     

    CUSIP No. 219798105 13D Page 12 of 13 pages

     

    (c) From June 25, 2024 through July 11, 2024, pursuant to the 10b5-1 Plan, Carlyle Partners VI Cayman Holdings, L.P. disposed of 721,020 shares of Common Stock in a series of open-market transactions. Details by date, listing the number of shares of Common Stock disposed of and the weighted average price per share, are provided below. The Reporting Persons undertake to provide, upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for each transaction.

     

    Date   Shares Disposed Of   Price Range   Weighted Average Price Per Share
    June 25, 2024   41,299   $32.6905 to $32.9999   $32.893
    June 25, 2024   26,173   $33.00 to $33.7555   $33.1981
    June 26, 2024   17,568   $32.48 to $32.9998   $32.8964
    June 26, 2024   63,914   $33.00 to $33.7741   $33.2731
    June 27, 2024   46,380   $33.07 to $33.80   $33.5144
    June 28, 2024   18,795   $32.71 to $32.9995   $32.8281
    June 28, 2024   31,142   $33.00 to $33.56   $33.1786
    July 01, 2024   40,225   $31.61 to $31.9999   $31.8132
    July 01, 2024   32,067   $32.00 to $32.92   $32.2951
    July 01, 2024   6,740   $33.0102 to $33.9938   $33.5932
    July 01, 2024   2,078   $34.00 to $34.18   $34.0929
    July 02, 2024   397   $30.8799 to $30.9979   $30.9728
    July 02, 2024   86,057   $31.0016 to $31.68   $31.3606
    July 03, 2024   46,391   $30.6163 to $30.9999   $30.8379
    July 03, 2024   6,333   $31.00 to $31.40   $31.0816
    July 05, 2024   6,406   $30.6299 to $30.9996   $30.8503
    July 05, 2024   44,333   $31.0036 to $31.36   $31.1957
    July 08, 2024   57,007   $30.07 to $30.9989   $30.3458
    July 08, 2024   2,966   $31.00 to $31.55   $31.2852
    July 09, 2024   23,781   $30.00 to $30.33   $30.0706
    July 10, 2024   24,390   $30.00 to $30.23   $30.0931
    July 11, 2024   4,724   $30.10 to $30.9998   $30.6844
    July 11, 2024   91,594   $31.00 to $31.9998   $31.4080
    July 11, 2024   260   $32.00 to $32.0336   $32.0096

     

    (d) None.

     

    (e) Not applicable.

     

     

     

     

    CUSIP No. 219798105 13D Page 13 of 13 pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: July 15, 2024

     

      The Carlyle Group Inc.
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Chief Financial Officer
         
      Carlyle Holdings II GP L.L.C.
       
      By: The Carlyle Group Inc., its sole member
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Chief Financial Officer
         
      Carlyle Holdings II L.L.C.
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      CG Subsidiary Holdings L.L.C.
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      TC Group Cayman Investment Holdings, L.P.
       
      By: CG Subsidiary Holdings L.L.C., its general partner
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      TC Group Cayman Investment Holdings Sub L.P.
       
      By: TC Group Cayman Investment Holdings, L.P., its general partner
      By: CG Subsidiary Holdings L.L.C., its general partner
         
      By: /s/ Anne Frederick, attorney-in-fact
      Name: John C. Redett
      Title: Managing Director
         
      TC Group VI Cayman, L.L.C.
         
      By: /s/ Jeremy W. Anderson
      Name: Jeremy W. Anderson
      Title: Vice President
         
      TC Group VI Cayman, L.P.
       
      By: TC Group VI Cayman, L.L.C., its general partner
         
      By: /s/ Jeremy W. Anderson
      Name: Jeremy W. Anderson
      Title: Vice President
         
      Carlyle Partners VI Cayman Holdings, L.P.
       
      By: TC Group VI Cayman, L.P., its general partner
      By: TC Group VI Cayman, L.L.C., its general partner
         
      By: /s/ Jeremy W. Anderson
      Name: Jeremy W. Anderson
      Title: Vice President

     

     

    Get the next $QDEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QDEL

    DatePrice TargetRatingAnalyst
    5/8/2025$44.00Hold → Buy
    Jefferies
    12/11/2024$44.00 → $50.00Neutral → Buy
    Citigroup
    12/10/2024$43.00Hold
    Jefferies
    9/19/2024$42.00 → $50.00Neutral
    UBS
    9/5/2024$40.00 → $57.00Hold → Buy
    Craig Hallum
    3/4/2024$70.00 → $42.00Neutral → Sell
    UBS
    2/14/2024$66.00 → $37.00Neutral → Underweight
    JP Morgan
    12/11/2023$95.00 → $72.00Buy → Neutral
    Citigroup
    More analyst ratings

    $QDEL
    SEC Filings

    See more
    • SEC Form 8-K filed by QuidelOrtho Corporation

      8-K - QuidelOrtho Corp (0001906324) (Filer)

      5/27/25 4:31:27 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SD filed by QuidelOrtho Corporation

      SD - QuidelOrtho Corp (0001906324) (Filer)

      5/22/25 4:05:30 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - QuidelOrtho Corp (0001906324) (Filer)

      5/7/25 4:07:42 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Blaser Brian J. bought $249,878 worth of shares (6,033 units at $41.42) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      12/13/24 4:12:57 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Busky Joseph M bought $99,663 worth of shares (2,150 units at $46.35) (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      2/26/24 6:48:23 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • QuidelOrtho upgraded by Jefferies with a new price target

      Jefferies upgraded QuidelOrtho from Hold to Buy and set a new price target of $44.00

      5/8/25 9:44:58 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho upgraded by Citigroup with a new price target

      Citigroup upgraded QuidelOrtho from Neutral to Buy and set a new price target of $50.00 from $44.00 previously

      12/11/24 8:21:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Jefferies initiated coverage on QuidelOrtho with a new price target

      Jefferies initiated coverage of QuidelOrtho with a rating of Hold and set a new price target of $43.00

      12/10/24 8:01:07 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

      ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

      6/3/25 4:10:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Participate in Upcoming Investor Conferences

      QuidelOrtho Corporation (NASDAQ:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in two upcoming investor conferences: William Blair 45th Annual Growth Stock Conference, Wednesday, June 4, 2025 Members of QuidelOrtho's management team will participate in a presentation at 9:00 a.m. ET / 6:00 a.m. PT. Jefferies Global Healthcare Conference, Thursday, June 5, 2025 Members of QuidelOrtho's management team will participate in a fireside chat at 8:45 a.m. ET / 5:45 a.m. PT. Interested parties can access the liv

      5/22/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Rhoads Ann D

      4/A - QuidelOrtho Corp (0001906324) (Issuer)

      6/3/25 4:08:16 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chief Financial Officer Busky Joseph M. was granted 5,392 shares and covered exercise/tax liability with 2,466 shares, increasing direct ownership by 17% to 19,943 units (SEC Form 4)

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      6/3/25 4:03:54 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Director Polan Mary Lake Ph D

      4 - QuidelOrtho Corp (0001906324) (Issuer)

      6/2/25 4:26:56 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Financials

    Live finance-specific insights

    See more
    • QuidelOrtho Announces Strategy to Accelerate Growth in Molecular Diagnostics

      ―Company Intends to Acquire LEX Diagnostics Upon U.S. FDA Clearance――Company Plans to Discontinue Savanna® Platform Development――Company Reaffirms Full Year 2025 Financial Guidance ――Company to Host Conference Call Today at 5:00 p.m. ET― SAN DIEGO, June 3, 2025 /PRNewswire/ -- QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced a refocusing of its molecular diagnostics strategy. This strategy includes the intent to acquire full ownership of LEX Diagnostics after 510(k) clearance by the U.S. Food and Drug Administrat

      6/3/25 4:10:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Reports First Quarter 2025 Financial Results

      ― Total revenue of $693 million, growth of 5% as reported and 6% in constant currency, excluding COVID-19 and Donor Screening ― ― Strong execution on cost-savings initiatives driving improved margins and profitability ― ― Company maintains full-year 2025 financial guidance ― First Quarter 2025 Results (all comparisons are to the prior year period) Total revenue was $693 million, as reported Non-respiratory revenue was $573 million, which was flat to the prior year period as reported and an increase of 2% in constant currency Labs revenue grew 5% as reported and 7% in constant currency Donor Screening revenue declined by 62% as the Company continues to wind down the U.S. portion of

      5/7/25 4:05:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho to Report First Quarter 2025 Financial Results

      QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company") or ("QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results. Interested parties can access the call from the "Events & Presentations" section of the "Investor Relations" page of the Company's website at https://ir.quidelortho.c

      4/23/25 4:30:00 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • QuidelOrtho Announces New R&D Executive Leader

      Jonathan Siegrist appointed as EVP of R&D and CTO QuidelOrtho Corporation (NASDAQ:QDEL), a global leader in innovative diagnostic solutions, is pleased to announce the appointment of Jonathan Siegrist, PhD, as its new Executive Vice President of Research and Development (R&D) and Chief Technology Officer (CTO), effective as of October 7, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241009251239/en/Jonathan Siegrist, EVP of R&D and CTO, QuidelOrtho (Photo: Business Wire) Siegrist brings a wealth of industry expertise and leadership experience with over 15 years in molecular diagnostics, microfluidic platforms, and biomedi

      10/9/24 7:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • QuidelOrtho Appoints Lee Bowman as Chief Human Resources Officer

      QuidelOrtho Corporation (NASDAQ:QDEL) is pleased to announce the appointment of Lee Bowman as Chief Human Resources Officer (CHRO). In this pivotal role, Bowman leads QuidelOrtho's human resources strategy, driving initiatives that bolster a dynamic and inclusive workplace culture. Bowman reports to Brian Blaser, President and Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910545042/en/Lee Bowman, Chief Human Resources Officer, QuidelOrtho (Photo: Business Wire) Bowman brings over 25 years of experience in human resources leadership, with a distinguished career that spans key roles in major industries.

      9/10/24 7:00:00 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $QDEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      12/6/24 10:11:24 AM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13D/A filed by QuidelOrtho Corporation

      SC 13D/A - QuidelOrtho Corp (0001906324) (Subject)

      11/21/24 5:10:19 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by QuidelOrtho Corporation

      SC 13G/A - QuidelOrtho Corp (0001906324) (Subject)

      11/14/24 1:28:35 PM ET
      $QDEL
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care